Plasma Cell Regulation by Purinergic Receptors
嘌呤能受体对浆细胞的调节
基本信息
- 批准号:10240081
- 负责人:
- 金额:$ 24.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:ATP ReceptorsAntibodiesAntibody titer measurementAutoantigensAutoimmune DiseasesAutoimmunityB-LymphocytesBindingBone GrowthBone MarrowCD8-Positive T-LymphocytesCartilageCationsCell CountCell MaintenanceCell SurvivalCell physiologyCellsChondrocytesChronicClinicalConnexinsDataDefectElementsExhibitsExtracellular SpaceFamilyG-Protein-Coupled ReceptorsGenerationsGraft RejectionHealthHumanImmunoglobulin-Secreting CellsInduced MutationKnockout MiceLongevityMaintenanceMembraneMemoryMessenger RNAMolecularMutant Strains MiceOdontoblastsOsteoblastsPathogenicityPharmaceutical PreparationsPlasma CellsPoisonPurinoceptorRegulationRoleSerumSignal PathwaySignal TransductionSpleenTestingTissuesTooth structureTransplantationVaccine DesignVertebratesWorkbasebonechronic painextracellularimmune activationimprovedimproved outcomeinhibitor/antagonistinsightmembermineralizationmutantnovelnovel strategiesnovel therapeutic interventionnovel therapeuticsosteoblast differentiationplasma cell differentiationpyridoxal phosphate-6-azophenyl-2&apos,4&apos-disulfonic acidreceptor
项目摘要
Project summary
Plasma cells that secrete antibodies against self-antigens pose a considerable threat to
human health. Moreover, because many plasma cells are exceptionally long-lived,
strategies are needed to deplete long-lived plasma cells (LLPCs) that secrete pathogenic
antibodies. This project centers on the hypothesis that LLPCs in bone marrow generate
requisite survival signals by sensing extracellular ATP with specific members of the
purinergic receptor (P2rX) family. Hence, we propose that compounds that selectively
poison relevant purinergic receptors will deplete LLPCs. To test our hypothesis, we will:
1) Establish the impact of P2rX inhibitors on LLPC generation and maintenance, and 2)
Determine the role of the purinergic receptor P2rX4 in early plasma cell induction and
LLPC maintenance. These studies will provide unique and needed insights into the
specialized survival mechanisms employed by LLPCs. This work supports our long-term
objective of developing strategies to effectively and specifically disable or deplete
problematic plasma cells.
项目总结
分泌自身抗原抗体的浆细胞对人类构成相当大的威胁
人类健康。此外,由于许多浆细胞的寿命非常长,
需要策略来耗尽分泌致病物质的长寿命浆细胞(LLPC)
抗体。这个项目的中心假设是,骨髓中的LLPC产生
通过感知细胞外的ATP与特定的成员
嘌呤能受体(P2rX)家族。因此,我们建议选择性地
毒物相关的嘌呤能受体将耗尽LLPC。为了检验我们的假设,我们将:
1)确定P2rX抑制剂对LLPC产生和维持的影响,以及2)
确定嘌呤能受体P2rX4在早期浆细胞诱导和分化中的作用
LLPC维护。这些研究将提供独特和必要的洞察
LLPC使用的专门生存机制。这项工作支持了我们长期的
制定有效和具体禁用或耗尽的战略的目标
有问题的浆细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M Allman其他文献
David M Allman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M Allman', 18)}}的其他基金
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10215534 - 财政年份:2020
- 资助金额:
$ 24.38万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10443660 - 财政年份:2020
- 资助金额:
$ 24.38万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10652461 - 财政年份:2020
- 资助金额:
$ 24.38万 - 项目类别:
Epigenetic Control of Plasma Cell Differentiation
浆细胞分化的表观遗传控制
- 批准号:
9105812 - 财政年份:2015
- 资助金额:
$ 24.38万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 24.38万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 24.38万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 24.38万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 24.38万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 24.38万 - 项目类别:














{{item.name}}会员




